Mesenchymal stem cell-derived interleukin-6 and vascular endothelial growth factor promote breast cancer cell migration

Journal of Cellular Biochemistry

Volumn 113, Issue 11, 2012, Pages 3363-3370

  De Luca, Antonella ^a   Lamura, Luana ^a   Gallo, Marianna ^a   Maffia, Veronica ^a   Normanno, Nicola ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

BREAST CANCER; IL 6; MESENCHYMAL STEM CELLS; MIGRATION; VEGF

Indexed keywords

BEVACIZUMAB; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN KINASE B; VASCULOTROPIN;

ARTICLE; BREAST CARCINOMA; CANCER CELL; CELL ASSAY; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG INHIBITION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; MESENCHYMAL STEM CELL; PRIORITY JOURNAL; WESTERN BLOTTING;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, NEUTRALIZING; BREAST NEOPLASMS; CELL COMMUNICATION; CELL MOVEMENT; CULTURE MEDIA, CONDITIONED; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-6; MESENCHYMAL STROMAL CELLS; MITOGEN-ACTIVATED PROTEIN KINASES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84866481797     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.24212     Document Type: Article

References (30)

1. Ara T, Declerck YA,. 2010. Interleukin-6 in bone metastasis and cancer progression. Eur J Cancer 46: 1223-1231.
2. Badache A, Hynes NE,. 2001. Interleukin 6 inhibits proliferation and, in cooperation with an epidermal growth factor receptor autocrine loop, increases migration of T47D breast cancer cells. Cancer Res 61: 383-391.
3. Beckermann BM, Kallifatidis G, Groth A, Frommhold D, Apel A, Mattern J, Salnikov AV, Moldenhauer G, Wagner W, Diehlmann A, Saffrich R, Schubert M, Ho AD, Giese N, Buchler MW, Friess H, Buchler P, Herr I,. 2008. VEGF expression by mesenchymal stem cells contributes to angiogenesis in pancreatic carcinoma. Br J Cancer 99: 622-631.
4. Danforth DN, Jr., Sgagias MK,. 1993. Interleukin-1 alpha and interleukin-6 act additively to inhibit growth of MCF-7 breast cancer cells in vitro. Cancer Res 53: 1538-1545.
5. De Luca A, Carotenuto A, Rachiglio A, Gallo M, Maiello MR, Aldinucci D, Pinto A, Normanno N,. 2008. The role of the EGFR signaling in tumor microenvironment. J Cell Physiol 214: 559-567.
6. De Luca A, Gallo M, Aldinucci D, Ribatti D, Lamura L, D'Alessio A, De Filippi R, Pinto A, Normanno N,. 2011. Role of the EGFR ligand/receptor system in the secretion of angiogenic factors in mesenchymal stem cells. J Cell Physiol 226: 2131-2138.
7. Deans RJ, Moseley AB,. 2000. Mesenchymal stem cells: Biology and potential clinical uses. Exp Hematol 28: 875-884.
8. El-Haibi CP, Karnoub AE,. 2010. Mesenchymal stem cells in the pathogenesis and therapy of breast cancer. J Mammary Gland Biol Neoplasia 15: 399-409.
9. Gallo M, De Luca A, Lamura L, Normanno N,. 2012. Zoledronic acid blocks the interaction between mesenchymal stem cells and breast cancer cells: Implications for adjuvant therapy of breast cancer. Ann Oncol 23: 597-604.
10. Gasparini G,. 2001. Clinical significance of determination of surrogate markers of angiogenesis in breast cancer. Crit Rev Oncol Hematol 37: 97-114.
11. Goldstein RH, Reagan MR, Anderson K, Kaplan DL, Rosenblatt M,. 2010. Human bone marrow-derived MSCs can home to orthotopic breast cancer tumors and promote bone metastasis. Cancer Res 70: 10044-10050.
12. Grothey A, Galanis E,. 2009. Targeting angiogenesis: Progress with anti-VEGF treatment with large molecules. Nat Rev Clin Oncol 6: 507-518.
13. Hall B, Andreeff M, Marini F,. 2007. The participation of mesenchymal stem cells in tumor stroma formation and their application as targeted-gene delivery vehicles. Handb Exp Pharmacol 180: 263-283.
14. Joyce JA, Pollard JW,. 2009. Microenvironmental regulation of metastasis. Nat Rev Cancer 9: 239.
15. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, Richardson AL, Polyak K, Tubo R, Weinberg RA,. 2007. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449: 557-563.
16. Knupfer H, Preiss R,. 2007. Significance of interleukin-6 (IL-6) in breast cancer (review). Breast Cancer Res Treat 102: 129-135.
17. Kuhn NZ, Tuan RS,. 2010. Regulation of stemness and stem cell niche of mesenchymal stem cells: Implications in tumorigenesis and metastasis. J Cell Physiol 222: 268-277.
18. Molloy AP, Martin FT, Dwyer RM, Griffin TP, Murphy M, Barry FP, O'Brien T, Kerin MJ,. 2009. Mesenchymal stem cell secretion of chemokines during differentiation into osteoblasts, and their potential role in mediating interactions with breast cancer cells. Int J Cancer 124: 326-332.
19. Morabito A, De Maio E, Di Maio M, Normanno N, Perrone F,. 2006. Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: Current status and future directions. Oncologist 11: 753-764.
20. Price DJ, Miralem T, Jiang S, Steinberg R, Avraham H,. 2001. Role of vascular endothelial growth factor in the stimulation of cellular invasion and signaling of breast cancer cells. Cell Growth Differ 12: 129-135.
21. Psaila B, Lyden D,. 2009. The metastatic niche: Adapting the foreign soil. Nat Rev Cancer 9: 285-293.
22. Sansone P, Bromberg J,. 2012. Targeting the interleukin-6/jak/stat pathway in human malignancies. J Clin Oncol 30: 1005-1014.
23. Sasser AK, Sullivan NJ, Studebaker AW, Hendey LF, Axel AE, Hall BM,. 2007. Interleukin-6 is a potent growth factor for ER-alpha-positive human breast cancer. FASEB J 21: 3763-3770.
24. Shen WH, Zhou JH, Broussard SR, Freund GG, Dantzer R, Kelley KW,. 2002. Proinflammatory cytokines block growth of breast cancer cells by impairing signals from a growth factor receptor. Cancer Res 62: 4746-4756.
25. Studebaker AW, Storci G, Werbeck JL, Sansone P, Sasser AK, Tavolari S, Huang T, Chan MW, Marini FC, Rosol TJ, Bonafe M, Hall BM,. 2008. Fibroblasts isolated from common sites of breast cancer metastasis enhance cancer cell growth rates and invasiveness in an interleukin-6-dependent manner. Cancer Res 68: 9087-9095.
26. Sullivan NJ, Sasser AK, Axel AE, Vesuna F, Raman V, Ramirez N, Oberyszyn TM, Hall BM,. 2009. Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells. Oncogene 28: 2940-2947.
27. Swartz MA, Iida N, Roberts EW, Sangaletti S, Wong MH, Yull FE, Coussens LM, Declerck YA,. 2012. Tumor microenvironment complexity: Emerging roles in cancer therapy. Cancer Res 72: 2473-2480.
28. Wanami LS, Chen HY, Peiro S, Garcia de Herreros A, Bachelder RE,. 2008. Vascular endothelial growth factor-A stimulates Snail expression in breast tumor cells: Implications for tumor progression. Exp Cell Res 314: 2448-2453.
29. Wu Y, Hooper AT, Zhong Z, Witte L, Bohlen P, Rafii S, Hicklin DJ,. 2006. The vascular endothelial growth factor receptor (VEGFR-1) supports growth and survival of human breast carcinoma. Int J Cancer 119: 1519-1529.
30. Xie G, Yao Q, Liu Y, Du S, Liu A, Guo Z, Sun A, Ruan J, Chen L, Ye C, Yuan Y,. 2012. IL-6-induced epithelial-mesenchymal transition promotes the generation of breast cancer stem-like cells analogous to mammosphere cultures. Int J Oncol 40: 1171-1179.